Principal Investigator
Dickran Kazandjian
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20220595
Clinical Trial Summary
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Myeloma
Contact Information
Phone Number
305-243-2647